The Effect of Anacetrapib on Vascular Function and Arterial Stiffness
NCT ID: NCT02931188
Last Updated: 2024-02-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
103 participants
OBSERVATIONAL
2017-01-31
2018-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Participants will be asked to provide a blood sample and pulse Wave Velocity/Pulse Wave Analysis and Flow Mediated Dilation will be carried out to assess blood vessel function and stiffness of the arteries. REVEAL-Vasc is an investigator led sub-study of HPS3/TIMI 55: REVEAL (Randomized Evaluation of the Effects of Anacetrapib through Lipid modification): A large-scale, randomized placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease (NCT01252953) which is coordinated by OXFORD CTSU.
No treatment will be received on this sub-study, therefore only participants who have been enrolled in HPS3/TIMI55 REVEAL in which participants received anacetrapib with atorvastatin or placebo will be considered for this trial.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification
NCT01252953
Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019)
NCT00685776
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022)
NCT01860729
Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease
NCT05202509
Preventing Anthracycline Cardiovascular Toxicity With Statins (PREVENT)
NCT01988571
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Anacetrapib
Participants who received anacetrapib, in addition to statin on the HPS3/TIMI 55: REVEAL trial.
Anacetrapib
No drug administration will occur on this sub-study. Participants will receive treatment on the main trial HPS3/TIMI 55: REVEAL (NCT01252953)
Statin
No drug administration will occur on this sub-study. Participants will receive treatment on the main trial HPS3/TIMI 55: REVEAL (NCT01252953)
Placebo
Participants who received placebo, in addition to statin on the HPS3/TIMI 55: REVEAL trial.
Statin
No drug administration will occur on this sub-study. Participants will receive treatment on the main trial HPS3/TIMI 55: REVEAL (NCT01252953)
Placebo
No drug administration will occur on this sub-study. Participants will receive treatment on the main trial HPS3/TIMI 55: REVEAL (NCT01252953)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Anacetrapib
No drug administration will occur on this sub-study. Participants will receive treatment on the main trial HPS3/TIMI 55: REVEAL (NCT01252953)
Statin
No drug administration will occur on this sub-study. Participants will receive treatment on the main trial HPS3/TIMI 55: REVEAL (NCT01252953)
Placebo
No drug administration will occur on this sub-study. Participants will receive treatment on the main trial HPS3/TIMI 55: REVEAL (NCT01252953)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Atrial fibrillation at time of assessment
* Inability to provide informed consent
* Inability to refrain from caffeine containing products for 6 hours prior to study visit
* Inability to refrain from smoking for 2 hours prior to study visit
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
British Heart Foundation Cambridge Centre of Excellence
UNKNOWN
Cambridge University Hospitals NHS Foundation Trust
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Joseph Cheriyan, MD
Consultant Clinical Pharmacologist & Physician/Associate Lecturer
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Joseph Cheriyan, MBChB, MA, FRCP
Role: PRINCIPAL_INVESTIGATOR
Cambridge University Hospitals NHS Foundation Trust
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Investigation Ward, Addenbrooke's Hospital
Cambridge, Cambridgeshire, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
REVEAL main trial clinicaltrials.gov record
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
REVEAL-Vasc
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.